Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(4.35)
# 409
Out of 5,081 analysts
54
Total ratings
36.59%
Success rate
46.26%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $66 → $75 | $27.75 | +170.27% | 2 | Nov 13, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $10.06 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $72.94 | +20.65% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.37 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $43.51 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $71.58 | +34.12% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $11.17 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $220.98 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $10.40 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $7.84 | - | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $18.16 | -28.36% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.95 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $55.99 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $101.50 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.49 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.57 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $37.82 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $180.75 | +61.55% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $463.13 | -20.11% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.37 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.58 | - | 1 | May 30, 2017 |
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $66 → $75
Current: $27.75
Upside: +170.27%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $10.06
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $72.94
Upside: +20.65%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.37
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $43.51
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $71.58
Upside: +34.12%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $11.17
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $220.98
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.40
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.84
Upside: -
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $18.16
Upside: -28.36%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.95
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $55.99
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $101.50
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.49
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.57
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $37.82
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $180.75
Upside: +61.55%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $463.13
Upside: -20.11%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.37
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.58
Upside: -